Dr Suldan Abdullahi

Directions Website

Dr Suldan Abdullahi Daignostic schemas, clinical pearls, infographics, upadates and insights regarding internal medicine.

20/10/2026
14/10/2026

“The most dangerous moment in medicine isn't when a doctor doesn't know the diagnosis.

It's when the doctor is wrong but no longer has any doubts.”

ADA / EASD 2026What Changes in practice ? Consesus report on  treatment of Type 2 Diabetes Mellitus .
06/10/2026

ADA / EASD 2026
What Changes in practice ? Consesus report on treatment of Type 2 Diabetes Mellitus .

MRCP course
05/10/2026

MRCP course

Dr suldan's MRCP COURSE

04/10/2026

Any anaemia gives you two numbers to start with.

MCV and reticulocyte count (corrected one).

Start with the reticulocyte count, not the MCV.

It asks one question: is the marrow responding or not?

High retic means the marrow is working fine and cells are being lost or destroyed somewhere.

Cause: Bleeding or haemolysis.

Nothing wrong with production.

Low retic means the marrow itself has failed to make them.

Now the MCV matters, because it tells you what the marrow was short of.

Low MCV: a building block is missing. Iron, or globin chains in thalassaemia, or the heme ring in sideroblastic anaemia.

High MCV: DNA synthesis failed.

The cytoplasm kept growing while the nucleus could not divide. B12, folate, drugs that block DNA.

Normal MCV: production itself was switched off. Chronic disease, renal failure with no erythropoietin, marrow infiltration, aplasia.

Retic tells you whether the marrow is trying. MCV tells you what it was missing.

03/10/2026

The best way, perhaps the only way, to change others is to become an example.

01/10/2026

🔴 What could change our diabetes practice?

1. 🫘 In CKD, eGFR alone tells only half the story.
Among transplant recipients with diabetes, CKD prevalence rose from 49.5% using reduced eGFR alone to 72.6% when albuminuria was also considered.
💡 Clinical message: Always think eGFR + UACR, not eGFR alone.

2. ⚠️ Normal glucose does NOT exclude dangerous ketosis.
PARTNER cases showed that people with T1D—particularly with SGLT2 inhibitor exposure—may develop clinically silent ketonaemia, especially with reduced insulin delivery, low-carbohydrate intake, illness or pump interruption.
💡 CME Pearl: When the clinical situation suggests ketosis, check ketones—not merely glucose. Continuous ketone monitoring is an emerging safety tool, not yet something required for every patient.

3. 🎯 “Low predicted risk” does not mean “low-risk diabetes.”
In the UK cohort, 11.8% of newly diagnosed T2D occurred despite low predicted risk. These patients were younger and leaner, yet had higher HbA1c, more subsequent insulin initiation and higher severe retinopathy and mortality.
💡 Clinical message: Don't let a reassuring risk score overrule clinical suspicion.

4. 📈 Metabolic trajectory may matter as much as a snapshot.
Longitudinal changes in insulin resistance/sensitivity indices added information for predicting future T2D. Interestingly, TyG and TG/HDL-C contributed particularly through their trajectories over time, rather than a single baseline measurement.
💡 Follow the metabolic movie—not just the photograph.

5. 💊 Don't always wait for monotherapy to fail.
Evidence presented from UKPDS follow-up, combination-treatment trials and VERIFY supports earlier proactive combination therapy for better glycaemic durability rather than therapeutic inertia.
💡 CME Pearl: “Treat-to-failure” is increasingly giving way to “treat-to-preserve.”

6. 👴 But early combination is NOT for everybody.
Frailty, dementia, multimorbidity, CKD/liver disease, polypharmacy, hypoglycaemia risk, adherence and treatment burden may make stepwise intensification—or even de-intensification—more appropriate.
💡 The best regimen is not necessarily the regimen with the most drugs; it is the one matched to the patient.

7. 🧑 Young-onset T2D deserves special cardiometabolic attention.
Compared with later-onset T2D, young-onset patients had persistently higher HbA1c and LDL-C and underwent HbA1c/LDL-C testing less frequently. The LDL-C disparity did not narrow with time.
💡 Don't treat young age as cardiovascular reassurance.

8. 📱 Adolescence → young adulthood is a vulnerable diabetes transition.
Among 1,631 people aged 11–22 years with T1D, only about 22% met both stated CGM targets, and target attainment declined with increasing age; hyperglycaemia was the major barrier.
💡 Technology needs to be accompanied by age-specific behavioural and healthcare support.

9. 🔥 Tirzepatide early in T2D: beyond HbA1c and kilograms.
At 104 weeks in SURPASS-EARLY, HbA1c fell to 5.56% vs 6.35% with intensified conventional care, while weight fell by about 15.8 vs 6.5 kg. OGTT-derived measures also indicated greater improvement in β-cell function and insulin sensitivity.
💡 This raises an important concept: early incretin-based treatment may modify multiple components of the metabolic phenotype—not simply glucose.

10. 💉 Before simply escalating basal insulin, reconsider the strategy.
In SUSTAIN OPTIMIZE, adding semaglutide 2.0 mg weekly while reducing basal insulin produced greater HbA1c reduction, 8-kg weight loss, lower insulin requirement and TIR 81.2% vs 64.3% with titrated glargine alone—roughly 4 extra hours/day in range, without increased TBR.

💡 Sometimes the better intensification is less insulin + an effective complementary therapy, rather than progressively more basal insulin.

11. 🎯 In DKD, look beyond BMI—visceral adiposity may matter.
In T2D with visceral obesity, >10% reduction in visceral fat area was associated with more albuminuria improvement and slower eGFR decline; the VFA-reduction group had a 2.53-fold higher probability of albuminuria improvement.
💡 Where the fat is—and how it changes—may matter to the kidney. Importantly, this was an association from a prospective cohort, not proof of causality.

12. ⚡ Painful diabetic neuropathy may have a neuromodulation option in selected refractory patients.
With 10-kHz spinal cord stimulation, 93.1% of per-protocol participants achieved ≥50% pain reduction at 6 months versus 0% with conventional medical management; sensory improvement was also demonstrated and persisted through 12 months.
💡 Particularly interesting: the signal was not limited to analgesia—objective sensory-function improvement was also reported.

🔥 TAKE-HOME

Diabetes care in 2026 is moving from “lower the HbA1c” → to “identify the phenotype, protect the organs, preserve function and individualize early.”

The 5 shifts worth remembering:
eGFR → eGFR + UACR | Glucose → Glucose + Ketones | BMI → Adiposity phenotype | Stepwise failure → Timely combination | HbA1c → CGM + organ outcomes + quality of life

Source: Essence of EASD 2026, Milan, Day 2. These are conference-study findings as presented in the uploaded document; several should be viewed as emerging evidence rather than automatic changes to clinical guidelines.

𝐖𝐇𝐎 𝐌𝐀𝐋𝐀𝐑𝐈𝐀 𝐆𝐔𝐈𝐃𝐄𝐋𝐈𝐍𝐄𝐒 𝟐𝟎𝟐𝟔 — 𝐓𝐎𝐏 𝐂𝐋𝐈𝐍𝐈𝐂𝐀𝐋 𝐏𝐄𝐀𝐑𝐋𝐒The WHO Guidelines for Malaria, 10 September 2026 replace previous vers...
25/09/2026

𝐖𝐇𝐎 𝐌𝐀𝐋𝐀𝐑𝐈𝐀 𝐆𝐔𝐈𝐃𝐄𝐋𝐈𝐍𝐄𝐒 𝟐𝟎𝟐𝟔 — 𝐓𝐎𝐏 𝐂𝐋𝐈𝐍𝐈𝐂𝐀𝐋 𝐏𝐄𝐀𝐑𝐋𝐒

The WHO Guidelines for Malaria, 10 September 2026 replace previous versions and include important updates involving pregnancy/HIV, transmission-blocking primaquine, infants

Address

Cairo

Alerts

Be the first to know and let us send you an email when Dr Suldan Abdullahi posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share